THYROCARE Thyrocare Technologies Q4 FY26 results (Jan–Mar 2026) and concall
Thyrocare Technologies delivered robust Q4 and full-year FY26 results, driven by strong revenue growth across its franchisee and partnership businesses, and strategic expansion into specialty diagnostics. The company achieved 21% consolidated revenue growth for FY26 and 20% for Q4 FY26, with PAT growing 81% for the full year. Key highlights include a 23% increase in test volumes, expansion of its lab network to 40 labs in India, and strategic investments in genomics and allergy testing. While facing some headwinds in its partnership segment and potential raw material price volatility, manageme
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 19.8%, net profit up 122.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 177 | 166 | 187 | 193 | 217 +23% | 196 +18% | 224 +20% |
| EBITDA | 48 | 42 | 57 | 58 | 71 +48% | 58 +38% | 75 +32% |
| Net profit | 26 | 19 | 22 | 38 | 48 +85% | 28 +47% | 49 +123% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
